IP Library Granted Patent US 11,413,316
Granted Patent B2
US 11,413,316 · App. 16/461,595 · Granted Aug 16, 2022

In vitro production of muscle stem cells

Inventors: Omid Mashinchian (Lausanne, CH); Jerome Feige (Crissier, CH); Conrad Florian Bentzinger (Sherbrooke, CA)
Assignee: Societe des Produits Nestle S.A.
A61K35/34A61K35/44A61K35/545C12N5/0697C12N2501/727C12N2502/1323C12N2502/28C12N2502/45C12N2513/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,413,316
App. No.
16/461,595
Granted
Aug 16, 2022
Kind
B2
Abstract

An in vitro method of producing a population of muscle stem cells comprising co-culturing pluripotent stem cells, embryonic fibroblast cells and endothelial cells in 3D cell culture.

Claims (25)

1. A method of producing a population of muscle stem cells in vitro, the method comprising:

admixing pluripotent stem cells, embryonic fibroblasts and endothelial cells and establishing at least one 3D spheroid comprising the pluripotent stem cells, the embryonic stem cells and the endothelial cells;

co-culturing the pluripotent stem cells, the embryonic fibroblast cells and the endothelial cells in a 3D cell culture, wherein

(a) the pluripotent stem cells and the embryonic fibroblast cells are in a ratio of about 0.3-4.1;

(b) the pluripotent stem cells and the endothelial cells are in a ratio of about 0.3-4:1; and

(c) the embryonic fibroblast cells and the endothelial cells are in a ratio of about 1-2:1; and

wherein the muscle stem cells produced are skeletal muscle stem cells.

2. The method of claim 1 , wherein the pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells.

3. The method of claim 1 , wherein the pluripotent stem cells are human pluripotent stem cells.

4. The method of claim 1 , wherein the embryonic fibroblast cells are mammalian embryonic fibroblast cells.

5. The method of claim 1 , wherein the endothelial cells are mammalian endothelial cells.

6. The method of claim 1 , wherein the pluripotent stem cells, the embryonic fibroblast cells and the endothelial cells are in a ratio of about 0.3-4:1:1.

7. The method of claim 1 , wherein the pluripotent stem cells, the embryonic fibroblast cells and the endothelial cells are co-cultured for about 3-30 days.

8. The method of claim 1 , wherein the 3D cell culture further comprises fibroblasts other than embryonic fibroblasts, smooth muscle cells and/or myoblast cells.

9. The method of claim 1 , wherein the muscle stem cells are Pax7 + and/or NCAM + and/or CD82 + .

10. The method of claim 1 , wherein the muscle stem cells are negative for commitment factors.

11. The method of claim 1 , wherein the pluripotent stem cells and the embryonic fibroblast cells are in a ratio of about 1.5-2.5:1.

12. The method of claim 1 , wherein the pluripotent stem cells and endothelial cells are in a ratio of about 1.5-2.5:1.

13. The method of claim 1 , wherein the endothelial cells are mouse or human endothelial cells.

14. The method of claim 1 , wherein

(a) the pluripotent stem cells and the embryonic fibroblast cells are in a ratio of about 2:1;

(b) the pluripotent stem cells and the endothelial cells are in a ratio of about 2:1; and/or

(c) the embryonic fibroblast cells and the endothelial cells are in a ratio of about 1:1.

15. The method of claim 1 , wherein the muscle stem cells are at least two selected from the group consisting of Pax7 + , NCAM + , CD82 + , GATA4 + and FGF5 + .

16. The method of claim 1 , wherein the muscle stem cells are at least two selected from the group consisting of Myf5 − , Myogenin − , MyoD − and MYH2 − .

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2022
From: MASHINCHIAN, OMID; FEIGE, JEROME; BENTZINGER, CONRAD FLORIAN
To: NESTEC S.A.
Reel/Frame 060145/0313 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →